EUCTR2009-011357-41-DE进行中（未招募）不适用
A long-term, open, follow-up of the immunogenicity and safety of GlaxoSmithKline Biologicals’ HPV-16/18 L1 VLP AS04 vaccine in healthy female subjects up to 10 years after administration of the first vaccine dose in study HPV 014. - HPV-060 EXT 014 Y5-10
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 667
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •Subjects who the investigator believes that they can and will comply with the requirements of the protocol.
- •A female who enrolled in study HPV-014 and received three doses of HPV-16/18 vaccine.
- •Written informed consent obtained from the subject.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 647
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 20
排除标准
- •Use of any investigational or non-registered product (drug or vaccine) or planned use during the study period.
- •Chronic administration (defined as more than 14 consecutive days) of immunosuppressants or other immune-modifying drugs occurring less than three months prior to blood sampling. For corticosteroids, this will mean prednisone, >= 0.5 mg/kg/day, or equivalent. Inhaled and topical steroids are allowed.
- •Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product (pharmaceutical product or device).
- •Administration of immunoglobulins and/or any blood products within the three months preceding blood sampling.
- •Administration or planned administration of any HPV vaccine, other than the three doses of HPV-16/18 vaccine administered in study HPV 014.
研究者
相似试验
进行中（未招募）
不适用
A long-term, open, follow-up of the immunogenicity and safety of GlaxoSmithKline Biologicals’ HPV-16/18 L1 VLP AS04 vaccine in healthy female subjects up to 10 years after administration of the first vaccine dose in study HPV 014. - HPV-060 EXT 014 Y5-10For active immunization of women from the age of 10 years onwards to prevent cervical cancer (squamous-cell carcinoma and adenocarcinoma) by protecting against incident and persistent infections, cytological abnormalities including atypical squamous cells of undetermined significance (ASC US) and cervical intraepithelial neoplasia (CIN), CIN1 and pre-cancerous lesions (CIN2 and CIN3), caused by oncogenic human papillomavirus (HPV) types 16 and 18.EUCTR2009-011357-41-PLGlaxoSmithKline Biologicals667
进行中（未招募）
不适用
A long-term, open follow-up of the immunogenicity and safety of GlaxoSmithKline Biologicals’ HPV-16/18 VLP/AS04 vaccine in healthy female subjects up to 10 years after administration of the first vaccine dose in study HPV-013. - HPV-025 EXT 013For the prevention of high-grade cervical intraepithelial neoplasia (CIN grades 2 and 3) and cervical cancer causally related to human papillomavirus (HPV) types 16 and 18.EUCTR2008-000369-44-DEGlaxoSmithKline Biologicals600
进行中（未招募）
1 期
Administration of 9valent vaccine against papillomavirus in HIV-positive womeEUCTR2018-000228-33-BECHU Saint-Pierre200
进行中（未招募）
不适用
A Long Term Safety and Effectiveness Study of Gardasil (V501) in Preadolescents and Adolescents (V501-018)HPVMedDRA version: 18.1Level: LLTClassification code 10063001Term: Human papilloma virus infectionSystem Organ Class: 100000004862EUCTR2014-005717-23-Outside-EU/EEAMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.1,575
进行中（未招募）
1 期
A Long-Term Safety and Immunogenicity Follow-up of Healthy Adults Vaccinated with One Dose of Smallpox Vaccine (LISTER Strain).Five year follow-up of healthy adults already vaccinated in a previous trialEUCTR2006-000715-19-FRSanofi Pasteur SA230